February 27, 2015 4:13 PM ET


Company Overview of Albireo AB

Company Overview

Albireo AB, a biotechnology company, focuses on the development of therapeutic drugs for gastrointestinal and liver diseases. Its pipeline programs include Elobixibat IBAT inhibitor for IBS-C and chronic constipation; A4250 IBAT inhibitor for cholestatic liver diseases; A3384 for bile acid mal-absorption; locally active PPAR agonists for IBD; IBAT inhibitor for type 2 diabetes and mellitus; and A3914 and A5425 NK antagonist for atopic dermatitis and psoriasis post-operative adhesions. Albireo AB was founded in 2008 and is based in Gothenburg, Sweden.

Arvid Wallgrens Backe 20

Gothenburg,  413 46


Founded in 2008


46 3 17 41 14 80


46 31 82 02 23

Key Executives for Albireo AB

Director of Finance & Operations
Chief Operating Officer and Director
Chief Medical Officer
Vice President of Development
Vice President of Pre-Clinical
Compensation as of Fiscal Year 2014.

Similar Private Companies By Industry

Company Name Region
Plant Science Sweden AB Europe
MIAB SA Europe
Episentec AB Europe
ModPro AB Europe
Xintela AB Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Albireo AB, please visit www.albireopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.